Abstract. New drugs that inhibit the osteoprotegerin (OPG)/receptor activator of NF-κB ligand (RANKL)/RANK pathway have demonstrated efficacy for the treatment of bone metastasis. Toxicities induced by these drugs, however, including osteonecrosis of the jaw and hypocalcemia, may adversely affect therapy. The aim of this study was to identify additional therapeutic targets that can be combined with OPG/RANKL/RANK pathway inhibition in the treatment of prostate cancer bone metastasis. We established a stable transfectant that produces high levels of OPG mRNA and protein from PC-3 human prostate cancer cells (PC3-OPG). The culture medium of PC3-OPG cells significantly inhibited the differentiation of mouse monocytes into mature osteoclasts. Furthermore, when PC3-OPG cells were injected into the bones of nude mice, bone destruction and tumor-induced osteoclast formation were reduced. Injection into bone of the mixtures containing equal amounts of green fluorescent protein (GFP)-expressing PC-3 cells (PC3-GFP) and PC3-OPG cells also reduced bone destruction, compared to the control mixture. PC3-GFP cells were subsequently isolated from bone tumors and used for microarray analysis to assess changes in gene expression following osteolytic tumor growth inhibition by OPG. We selected the top 10 upregulated genes based on results from microarrays and confirmed mRNA expression of each gene by RT-PCR. The expression patterns of retinol-binding protein 4 (RBP4) and placenta-specific 8 (PLAC8) were consistent with microarray results. Expression of these genes was also increased in the bone tumors of PC3-GFP/PC3-OPG-injected mice. Knockdown of both RBP4 and PLAC8 by siRNA inhibited the growth of PC-3 cells in vitro. Thus, RBP4 and PLAC8 may become new therapeutic targets for prostate cancer bone metastasis, in combination with OPG/RANKL/RANK pathway inhibition.

Introduction

Prostate cancer continues to be the most common cancer and the second leading cause of cancer deaths in the United States. It is estimated that 240,890 men were diagnosed with the disease and 33,730 died of it in 2011 (1). The skeleton is the most common site of distant metastasis in prostate cancer and bone metastasis was detected at autopsy in up to 90% of patients that died of the disease (2). Although metastatic lesions of prostate cancer in bone are predominantly osteoblastic, they can also be mixed or entirely osteolytic (3-6).

Skeletal-related events (SREs), such as pathologic fractures, spinal cord compression, surgery to bone and radiation to bone that occur frequently in patients with bone metastases, contribute substantially to morbidity and mortality and can reduce health-related quality of life. Management of bone metastases is therefore an important issue in the treatment of prostate cancer (7,8).

Disruption of homeostasis in the bone microenvironment plays a pivotal role in metastasis and tumor growth in bone. One key event is alteration of the bone remodeling system, which is closely related to bone metastasis (9). Three main factors associated with bone remodeling are receptor activator of NF-κB ligand (RANKL), RANK and osteoprotegerin (OPG). RANKL on the surface of osteoblasts binds to RANK on osteoclast progenitors and stimulates differentiation, activation and survival of these cells by recruiting tumor necrosis factor (TNF)-associated family of proteins, which act as cytosolic adaptor proteins (10). OPG, a 55-kDa secretory glycoprotein belonging to the TNF receptor superfamily, acts as a decoy receptor for RANKL and inhibits osteoclastogenesis and ovariectomy-induced bone loss (11). Mice lacking OPG were shown to exhibit a decrease in total bone density and arterial calcification (12).

RANKL inhibition has been studied in both in vitro and in vivo models of prostate cancer. In one study, treatment of mice with recombinant mouse OPG protein inhibited prostate

Correspondence to: Dr Hisanori Uehara, Department of Molecular and Environmental Pathology, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan
E-mail: uehara.h@tokushima-u.ac.jp

*Contributed equally

Key words: osteoprotegerin, retinol binding protein 4, placenta-specific 8, bone metastasis, prostate cancer
tumor-induced osteoclastogenesis and tumor growth in bone but had no effect on subcutaneous tumor growth, suggesting the absence of a direct antitumor effect (13). Similarly, when OPG-overexpressing C4-2 CaP cells were injected intrasosseously into immunodeficient mice, a reduction in tumor-burden was observed, although no effect on tumor growth was seen when these cells were grown subcutaneously (14). Treatment with RANKL inhibited osteoblastic growth of LuCaP35 cells growing in the bone of SCID mice (15). Collectively, these reports suggest that the OPG/RANKL/RANK pathway is a good molecular target for prevention of prostate cancer bone metastasis.

In addition to its role in regulating tumor-induced bone disease, however, the RANKL system may be associated with other distinct biological effects. For example, OPG may protect tumor cells from apoptosis induced by TRAIL (16,17). In addition, there are data showing that OPG positively regulates microvesSEL formation, whereas RANKL acts as angiogenic inhibitor (18). Thus, the RANKL system is complex. Furthermore, drugs used for the treatment of bone metastasis, which inhibit the OPG/RANKL/RANK pathway, have been reported to cause other toxicities including osteonecrosis of the jaw and hypocalcemia (19,20). Since these results of treatment may have adverse effects on therapy, it is necessary to identify additional therapeutic targets that can be combined with OPG/RANKL/RANK pathway inhibition in the treatment of bone metastasis.

In the present study, we established a stable transfectant that produces and secretes a high level of OPG protein from PC-3 human prostate cancer cells (PC3-OPG) and investigated its in vitro and in vivo characteristics. In addition, mixtures containing equal amounts of green fluorescent protein (GFP)-expressing PC-3 cells (PC3-GFP) and PC3-OPG or PC3-mock were injected into the bones of nude mice. PC3-GFP cells were subsequently isolated from bone tumors and used for microarray analysis to assess changes in gene expression following osteolytic tumor growth inhibition by OPG. The effects of knockdown of two upregulated genes were also examined in PC-3 cells. The overall goal of this study was to identify additional therapeutic targets that can be used in combination with OPG/RANKL/RANK pathway inhibition in the treatment of prostate cancer bone metastasis.

**Materials and methods**

**Cell culture.** The human prostate adenocarcinoma cell line PC-3 was maintained in MEM supplemented with 10% fetal bovine serum, 100 U/ml of penicillin G and 0.1 mg/ml streptomycin sulfate.

**Animals.** Four-week-old male athymic nude mice were purchased from Charles River Japan, Inc. (Yokohama, Japan). The mice were housed and maintained under specific pathogen-free conditions. Experiments were performed according to the Guideline for the Care and Use of Laboratory Animals of the University of Tokushima School of Medicine and all experimental protocols were approved by the Animal Committee.

**Construction of expression vectors and transfection.** The mammary expression vectors, pIRESneo3 and pAcGFP-C1 were purchased from Clonetech Inc. (Mountain View, CA, USA). Human OPG cDNA was obtained by reverse-transcription polymerase chain reaction (RT-PCR) of total RNA from PC-3 cells. Reverse-transcription was conducted at 42°C for 60 min, after which the temperature was increased to 72°C for 15 min, using SuperScript II reverse transcriptase and random hexamers (Invitrogen, Carlsbad, CA, USA). The obtained total cDNA was then amplified by polymerase chain reaction (PCR) following a thermal cycling program of 94°C for 10 min for initial denaturation, 40 cycles of 94°C for 30 sec, 55°C for 1 min and 72°C for 1 min for amplification and a final extension at 72°C for 10 min. Specific primers for hOPG were designed as follows: Eco-hOPG-F (sense) 5'-GAATTCATGACAACAGTTGCTGTGCA-3', Not-hOPG-R (antisense) 5'-GGCGCCCGCCACATTTCAGGTATAACGAC-3'. The OPG cDNA fragment was subcloned into the pIRESneo3 vector at the EcoRI and NotI restriction sites and the resulting vector was designated as pIRES-OPG. Sequences were further confirmed using an ABI PRISM® 3100-Avant Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).

A dose of 13.6 µg of control pIRESngeo3, pIRES-OPG or pAcGFP-C1 vectors was introduced into PC-3 cells (4x10⁵ cells/100-mm dish) using TransFast™ transfection reagent (Promega, Madison, WI, USA) according to the manufacturer's protocol. Transfectants were cultured in complete medium for 48 h and then selected for 72 h with 1 mg/ml of G418 sulfate (Promega). After selection, G418-resistant cells were routinely maintained in a medium containing 0.1 mg/ml G418. These stable transfectants were designated as PC3-mock, PC3-OPG and PC3-GFP, respectively.

**Semi-quantitative RT-PCR.** OPG mRNA levels were determined by semi-quantitative RT-PCR. Total RNA was isolated using an RNeasy® Mini kit (Qiagen GmbH, Hilden, Germany) from 5x10⁵ PC3-mock or PC3-OPG cells. After quantification of the RNA concentration, 1 µg of total RNA was subjected to RT-PCR. Reaction conditions were the same as described in ‘Construction of expression vectors and transfection’, except for the number of amplification cycles (30 cycles). In addition to OPG, β-actin was also amplified as an internal standard. The sequences of specific primers for β-actin were as follows: β-actin-F (sense) 5'-TAC AAT GAG CTG CGT GTGG-3', β-actin-R (antisense) 5'-AGA TGG GCA CAG TGT GGG-3'. RT-PCR products were separated by agarose gel electrophoresis and visualized using a UV illuminator.

**Enzyme-linked immunosorbent assay (ELISA) for OPG.** The concentration of OPG in the culture medium was determined by use of a RayBio® Human Osteoprotegerin ELISA kit (RayBiotech, Norcross, GA, USA). PC3-mock and PC3-OPG cells were seeded at 4x10⁵ cells/ml of medium/well onto 6-well plates and incubated for 72 h at 37°C in the presence of 1 mg of G418. After incubation, culture media were collected, centrifuged to remove cell debris and pre-diluted 100-fold before ELISA. These experiments were performed in duplicate. All values are means ± SD.

**Tartrate-resistant acid phosphatase (TRAP) assay.** Mouse monocytes (Primary Cell, Sapporo, Japan) were plated in 96-well plates at 4x10⁴ cells/well. After pre-incubation over-
night, cells were treated with 100 µl supernatants from cultured PC3-mock or PC3-OPG cells (72-h culture at 4x10⁵ cells/2 ml) for 10 days, in the presence of 10 ng/ml M-CSF and RANKL (R&D Systems, Inc., Minneapolis, MN, USA). After incubation, cells in plates were washed with PBS, fixed with 3.7% phosphate-buffered formaldehyde and permeabilized with 100% ethanol. These cells were then stained with TRAP-staining solution (5 µg of Naphtol AS-MX phosphate and 30 mg of Fast red violet LB salt (Sigma, St. Louis, MO, USA) in 50 ml of TRAP buffer (50 mM sodium tartrate and 45 mM sodium acetate)] and stained osteoclasts were counted under a microscope. Experiments were performed in n=6 and repeated twice. All values are means ± SD.

Bone metastasis model in nude mice. Intratibial injections of PC3-mock, PC3-OPG or equal mixtures of PC3-GFP with PC3-mock or PC3-OPG were performed as described previously (21). Briefly, PC3-mock and PC3-OPG cells (5x10⁶ cells/mouse) were trypsinized, washed once in PBS and resuspended in Ca²⁺- and Mg²⁺-free Hank's balanced salt solution at 5x10⁶ cells/20 µl. For injection of mixed prostate cancer cells, suspensions of PC3-GFP, PC3-mock and PC3-OPG cells were prepared at 2.5x10⁶ cells/10 µl and equal amounts of the PC3-GFP suspension and suspensions of PC3-mock or PC3-OPG (totally 5x10⁶ cells/mouse) were mixed. Prior to the intratibial injections, the mice were anesthetized with a ketamine hydrochloride (12 mg/ml)/xylazine (8 mg/ml) mixture. After precutaneous intraosseal injection was performed by drilling a 26-gauge needle into the tibia proximal to the tuberositas tibia, a 20-µl tumor cell suspension was further inserted. After 9 weeks of observation, the mice were anesthetized, placed in a prone position and their hind limbs were subjected to radiography after which the animals were sacrificed and tumor incidence, the weight of the leg (excised at the knee joint) and the presence of intraabdominal lymph node metastases (incidence) were recorded. Bone tumors formed after the injection of mixed prostate cancer cells were partially used for microarray analysis.

Histological analyses. After measuring the weight, the legs were fixed in 10% phosphate-buffered formalin for 24 h at room temperature, washed with PBS for 30 min and decalciified with 10% EDTA (pH 7.4) for 14 days at 4°C. Tissues were then embedded in paraffin and sectioned at 3.5-4 µm. Detection of osteoclasts was conducted by TRAP-staining. Sections were deparaffinized with xylene, dehydrated with ethanol, washed with PBS and stained with TRAP-staining solution for 1 h at 37°C. Subsequently, sections were washed with PBS and counterstained with hematoxylin. Osteoclast density was calculated based on the number of TRAP-positive cells per 1 mm of bone tissue contacting the tumor region. Immunocytochemical staining was performed using the ChemMate EnVision kit/horseradish peroxidase (DakoCytomation, Carpentaria, CA, USA). Mouse monoclonal antibody for Ki-67 (DakoCytomation, Glostrup, Denmark), rabbit monoclonal antibodies for GFP (Cell Signaling, Danvers, MA) and RBP4 (Abcam, Cambridge, MA) and rabbit polyclonal antibodies for PLAC8 (Abcam) were used as primary antibodies. Sections were heated in 0.01 M citrate buffer (pH 6.0) for 10 min in a pressure cooker for antigen retrieval. Primary antibodies were added to the slides at a dilution of 1:50 and incubated for 1 h at room temperature. After washing with PBS, each slide was treated with horseradish peroxidase-conjugated secondary antibody for 40 min. Visualization was completed using 3,3’-diaminobenzidine and the sections were counterstained with Mayer's hematoxylin (Muto Pure Chemicals, Tokyo, Japan).

Microarray analysis. Bone tumors formed after the injection of mixed prostate cancer cells were minced with a sharp-edged knife and cultured for 1 week in MEM supplemented with 10% fetal bovine serum. The cells were then harvested using 1 mM EDTA. PC3-GFP cells were isolated from the mixture that included PC3-mock or PC3-OPG using fluorescence-activated cell sorting (FACS) and the EPICS® XL-MCL (Beckman Coulter, Fullerton, CA, USA). Total RNA from PC3-GFP cells was isolated using an RNeasy Mini kit (Qiagen, Valencia, CA, USA). The relative purity of the RNA was measured using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). RNA expression was analyzed using a GeneChip® Human Gene 1.0 ST Array (Affymetrix, Santa Clara, CA, USA) that contains 28,869 oligonucleotide probes for known and unknown genes. First strand cDNA was synthesized from 300 ng of total RNA using GeneChip Whole Transcript (WT) cDNA Synthesis and Amplification kit (Affymetrix) according to the manufacture’s protocol. cRNA (10 µg) were added into the second-cycle cDNA reaction and this cDNA was fragmented and end-labeled with the GeneChip WT Terminal Labeling kit (Affymetrix). Approximately 5.5 µg of labeled DNA target was hybridized to the Affymetrix GeneChip Human Gene 1.0 ST Array at 45°C for 17 h on a GeneChip Hybridization 640 (Affymetrix) according to the manufacturer’s instructions. Hybridized arrays were washed and stained on a GeneChip Fluidics Station 450 and scanned using a GeneChip Scanner 3000 7G (Affymetrix), after which CEL files were generated for each array. This analysis was supported by the Support Center for Advanced Medical Sciences, the University of Tokushima Graduate School, Institute of Health Biosciences.

RNAl interference. PC-3 cells were seeded on 60-mm dishes and preincubated overnight at 37°C. The following day, the cells were transfected with negative universal control siRNA (Invitrogen), RBP-4 siRNA (ID SASI_Hs01_00141628; Sigma) and PLC8 siRNA (ID SASI_Hs01_00127245; Sigma) with Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s protocol. After transfection, cells were reseeded on 96-well microplates (5x10⁴ cells/well) and preincubated overnight at 37°C. The culture medium was then replaced with 100 µl of fresh complete medium and viable cells were counted by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method after incubation for 24 h. Total RNAs from surplus cells were also isolated and RT-PCR analysis was conducted to confirm the effects of knockdown. The conditions for RT-PCR were described in ‘Semi-quantitative RT-PCR.’ The sequences of specific primers for RBP-4 and PLC8 were as follows: RBP-4-F (sense) 5’-GAGGGCGACTGCCGAGTGA-3’, RBP-4-R (antisense) 5’TGGAGATCCAGAGGGCGGA-3’, PLC8-F (sense) 5’TCTCCACGCGCAAAGAATTTCC-3’ and PLC8-R (antisense) 5’GGACCGGGACGACTCCAG-3’.
Statistical analyses. The two-tailed Student’s t-test was employed for analysis of OPG ELISA, MTT assay, in vitro TRAP assays, comparison of the average weights of hind legs, densities of osteoclasts and Ki-67 indices. Fisher’s exact probability test was used for comparison of the incidence of lymph node metastasis. In all cases, a probability level of less than 0.05 (P<0.05) was considered significant.

Results

Characteristics of PC3-OPG. Using a PC-3 cell line, we established transfected cells that highly express OPG. The level of OPG mRNA in PC3-OPG cells, assessed by RT-PCR, was higher than that in the control vector-transfected cells, PC3-mock (Fig. 1A). This RT-PCR reaction was conducted under semi-quantitative conditions with 25 cycles of amplification. The level of OPG protein secreted into the culture media as measured by ELISA, was also higher in PC3-OPG cells than in PC3-mock cells. Indeed, culture media from PC3-mock contained 154±31 pg/ml OPG, whereas the level of OPG in PC3-OPG cells was 225-fold greater than that in PC3-mock cells (34,772±5,720 pg/ml, Fig. 1B). The growth rate of these cells was examined by the MTT assay, by calculating the percentage (%) of the OD\textsubscript{550} in 0 h-cultured cells. There were no significant differences at any of the time-points measured (24-, 48- and 72-h-culture) (Fig. 1C).

Inhibitory effect of culture supernatant from PC3-OPG cells on the differentiation of mouse monocytes to osteoclasts. Supernatants from 3-day cultures of transfectants were tested to determine whether they could influence differentiation of mouse monocytes into osteoclasts. Detection of osteoclasts was performed by the TRAP-staining method. The number of osteoclasts per field was 9.5±3.4 in the group treated with supernatants from PC3-mock cells. In contrast, a significant inhibition of osteoclastogenesis was found in the group treated

| Incidence of bone tumors | Average weight of hind legs (g) | Incidence of LN metastasis |
|-------------------------|-------------------------------|---------------------------|
| PC3-mock                | 100% (5/5)                    | 100% (5/5)                |
| PC3-OPG                 | 100% (5/5)                    | 20% (1/5)                 |

This analyses were done at the end of 9-week observation. LN, lymph node. Significantly different from PC3-mock at P<0.05 by Student’s t-test. Significantly different from PC3-mock at P<0.05 by Fisher’s exact probability test. Significantly different from PC3-mock at P<0.05 by Fisher’s exact probability test.
with supernatants from PC3-OPG cells and the number of osteoclasts per field was 0.2±0.4 (P<0.0005, Fig. 1D).

Effect of OPG on the development of prostate cancer cells in bone. We injected PC3-mock or PC3-OPG cells into the bones of nude mice. After 5 weeks, osteolytic lesions were observed radiographically in 2 out 5 mice in the PC3-OPG-injected group. Conversely, all of the mice in the PC3-mock-injected group had lytic bone lesions (data not shown). Furthermore, after 9 weeks, tumor growth and severe osteolysis were observed in PC3-mock-injected mice, whereas the bone structure of PC3-OPG-injected mice was still preserved (Fig. 2A). At week 9, expression of OPG mRNA was only detected in bone tumors from PC3-OPG-injected mice (Fig. 2B). Although bone lesions were observed in all mice, the average weight of the hind legs and the incidence of intraabdominal lymph node metastases were significantly reduced in PC3-OPG-injected mice (P<0.05, Table I). TRAP staining of bone lesions showed that the density of osteoclasts on the bone surface facing the tumor was significantly reduced in PC3-OPG-injected mice (19.9±5.8 per mm bone) compared to PC3-mock-injected mice (32.7±9.3 per mm bone; P<0.05, Fig. 2C). The number of Ki-67-positive cells in the tumors was also reduced in PC3-OPG-injected mice (47.4±14.4% in PC3-mock-injected mice compared to 21.5±5.4% in PC3-OPG-injected mice; P<0.01, Fig. 2D).

Analysis of gene expression in prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by OPG. For the detection of genes that were up/downregulated in prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by OPG, a mixture containing equal
amounts of PC3-GFP and either PC3-OPG or PC3-mock, was injected into the bones of nude mice. At week 9, similar to the results seen with PC3-OPG injection, bone structure was preserved in mice injected with the PC3-GFP/PC3-OPG mixture compared to those injected with the PC3-GFP/PC3-mock mixture (Fig. 3). PC3-GFP cells isolated from tumors from each group were used for microarray analysis. The top 10 genes that were up/downregulated in PC3-GFP cells that maintained in a high-OPG bone microenvironment are shown in Table II. The gene showing the greatest upregulation was insulin-like growth factor binding protein 5 (fold change 5.02) and the most downregulated gene was transforming growth factor, β-induced (fold change 0.12). All genes in Table II displayed >3-fold differential expression compared to control.

**Increase of RBP4 and PLAC8 expression in prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by OPG and the effect of RBP4 and PLAC8 knock-**

**Table II. Top 10 up/downregulated genes in PC3-GFP cells that maintained in a high-OPG bone microenvironment, identified by cDNA microarray analysis.**

| GenBank accession no. | Gene name | Fold changea |
|-----------------------|-----------|--------------|
| **Upregulated genes** |           |              |
| NM_000599             | Insulin-like growth factor binding protein 5 (IGFBP5) | 5.02 |
| NM_020775             | KIAA1324 (KIAA1324) | 4.67 |
| NM_000096             | Ceruloplasmin (ferroxidase) (CP) | 3.61 |
| NM_024727             | Leucine rich repeat containing 31 (LRRC31) | 3.59 |
| NM_032192             | Protein phosphatase 1, regulatory (inhibitor) subunit 1B (PPP1R1B), transcript variant 1 | 3.58 |
| NM_001080505          | Shisa homolog 3 (*Xenopus laevis*) (SHISA3) | 3.41 |
| NM_006744             | Retinol binding protein 4, plasma (RBP4) | 3.25 |
| NM_001145029          | Ankyrin repeat domain 30B (ANKRD30B) | 3.21 |
| NM_003657             | Breast carcinoma amplified sequence 1 (BCAS1) | 3.13 |
| NM_016619             | Placenta-specific 8 (PLAC8), transcript variant 2 | 3.02 |
| **Downregulated genes** |           |              |
| NM_000358             | Transforming growth factor, β-induced, 68 kDa (TGFBI) | 0.12 |
| NM_001143818          | Serpin peptidase inhibitor, clade B (ovalbumin), member 2 (SERPINB2), transcript variant 1 | 0.13 |
| NM_014439             | Interleukin 1 family, member 7 (ζ) (IL1F7), transcript variant 1 | 0.22 |
| NM_000963             | Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (PTGS2) | 0.23 |
| NM_002993             | Chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) (CXCL6) | 0.26 |
| NM_005554             | Keratin 6A (KRT6A) | 0.27 |
| NM_004385             | Versican (VCAN), transcript variant 1 | 0.27 |
| NM_001013398          | Insulin-like growth factor binding protein 3 (IGFBP3), transcript variant 1 | 0.29 |
| NM_018099             | Fatty acyl CoA reductase 2 (FAR2) | 0.29 |
| NM_002994             | Chemokine (C-X-C motif) ligand 5 (CXCL5) | 0.30 |

aThe microarray results of PC-3-GFP cells co-injected with PC-3-OPG cells were divided by those of cells co-injected with PC-3-mock.
down on the growth of prostate cancer cells. To examine the effect of knockdown of target genes by siRNA, we focused on the upregulated genes in Table II and confirmed mRNA expression of each gene by RT-PCR. Consequently, the expression patterns of RBP4 and PLAC8 were consistent with microarray results (Fig. 4A). Immunohistochemical staining of GFP, RBP4 and PLAC8 showed that bone tumors formed by injection of the mixture of PC3-GFP/PC3-mock or PC3-GFP/PC3-OPG, contained GFP-positive cells and the expression levels of both RBP4 and PLAC8 were increased in tumor cells from PC3-GFP/PC3-OPG-injected mice (Fig. 4B). Next, knockdown of RBP4 and PLAC8 by siRNA was performed in PC-3 cells. Each siRNA resulted in specific knockdown of the target gene without affecting expression of other genes (Fig. 4C). Knockdown of RBP4 and PLAC8 significantly inhibited the growth of PC-3 cells in vitro (P<0.0001, Fig. 4D).

Discussion

Although to date there are no aggressive therapies for bone metastasis, a valid strategy that targets the underlying molecular mechanisms of bone metastasis, has recently been developed.

Bisphosphonates including zoledronic acid, are frequently administered to delay or prevent SREs (8,22). Moreover, denosumab, the first fully human monoclonal antibody against RANKL that mimics the endogenous effect of OPG, was shown to be effective in reducing skeletal morbidity rate in breast and prostate cancer (23-26) and found to be more effective in delaying the time to first SREs and reducing the risk of first and subsequent SREs compared to zoledronic acid (27-29). Thus, new therapies aimed at decreasing osteoclast activity including inhibition of the OPG/RANKL/RANK pathway,
have demonstrated efficacy in the treatment of bone metastasis. There are, however, toxicities that have been reported to be associated with use of both denosumab and bisphosphonate (19,20), including osteonecrosis of the jaw and hypocalcemia, that may adversely affect therapies using these drugs. It is therefore necessary to identify additional therapeutic targets that can be combined with this type of therapy. In the present study, we demonstrated that OPG reduces osteolysis and cancer cell growth in a mouse model of bone metastasis and that expression of RBP4 and PLAC8, which were suggested to be associated with prostate cancer cell growth in vitro, was increased in maintained prostate cancer cells.

First, we examined whether expression of OPG in the androgen-independent human prostate cancer cell line PC-3, inhibits osteolysis and cancer cell growth in a mouse model of bone metastasis. Previous reports on the effects of OPG on bone metastasis of prostate cancers, were conducted using androgen-sensitive cells, although advanced prostate cancer eventually becomes androgen-independent (30). PC-3 differs from other androgen-sensitive cells not only in androgen receptor status, but also in status of p53 and in sensitivity to 1α,25-dihydroxyvitamin D3 and docetaxel (31-33). Furthermore, OPG has been reported to protect apoptosis of PC-3 cells induced by TRAIL (17) and promote angiogenesis (18). To generate an experimental system that enabled us to investigate effects of OPG, we established a PC-3-derived stable transfectant that highly expresses OPG, termed PC3-OPG. The relative expression levels of OPG mRNA and protein were clearly elevated in PC3-OPG cells compared with PC3-mock cells. In particular, a drastic increase (~225-fold compared with PC3-mock cells) in the level of OPG secretion was observed. Since it is reported that the constitutive expression level of OPG in non-treated PC-3 cells is ~750pg/ml (17), PC3-OPG can be regarded as a high-expressional subline derived from PC-3. By testing the growth rate of cells using the MTT method, we observed that the introduction of OPG cDNA was not cytotoxic. Similarly, a separate study showed no difference in the control of growth rates in another line of stable transfectants of OPG in C4-2 cells (9). The level of OPG secretion in that study was 8 ng/ml/10^6 cells. In contrast, our established transfectant expresses OPG protein at ~30 ng/ml/0.4x10^6 cells. This suggests that high expression of this factor is not fatal to cell proliferation in vitro. To test the effect of PC3-OPG-cultured medium on differentiation of monocytes into mature osteoclasts, we conducted an in vitro TRAP assay. Treatment of cells with PC3-OPG-cultured medium inhibited the generation of TRAP-positive cells indicating that the OPG from PC3-OPG cells is functionally effective as a decoy receptor for RANKL.

Administration of exogenous recombinant Fc-OPG protein was shown to inhibit tumor growth in bone (15), whereas implantation of breast cancer cells that overexpressed OPG aggravated tumor growth (34). Another study, however, reported that the prostate cancer-derived OPG-overexpressing cell line OPG-C4-2 grew more slowly in bone compared to vector control cells (14). Similarly, our results from the present study showed that the growth of PC3-OPG cells in bone was almost completely inhibited. At 9 weeks, tumors in the PC3-mock-injected group continued to develop and absolute osteolysis was seen in all mice. In contrast, no similar lesions were observed in PC3-OPG-injected mice. In addition, the average weight of the hind legs and the incidence of intraabdominal lymph node metastasis were significantly decreased in PC3-OPG-injected mice. Moreover, histological examination showed that the density of osteoclasts on the bone surface facing the tumor, as well as the number of Ki-67-positive cells in the tumors were reduced in PC3-OPG-injected mice. These results suggest that OPG acts mainly as an inhibitor of the growth of PC-3 cells that is associated with the surrounding bone environment. Its observed effects on protection from apoptosis in PC-3 cells and the promotion of angiogenesis, are limited in vivo.

To find new therapeutic targets associated with inhibition of the OPG/RANKL/RANK pathway, we injected mixtures containing equal amounts of PC3-GFP and PC3-mock or PC3-OPG cells into the bones of nude mice and analyzed PC3-GFP cells, which are not affected by internal OPG overexpression, using cDNA microarray overexpression. Bone destruction was reduced even by injection of the PC3-GFP/PC3-OPG mixture, compared to PC3-GFP/PC3-mock mixture. Tumor cells were cultured once because of the difficulty in separating tumors into single cells for sorting. After being cultured for 1 week, PC3-GFP cells were isolated and cDNA microarray analyses were performed. As shown in Table II, all of the top 10 genes that were up/downregulated in PC3-GFP cells following osteolytic tumor growth inhibition by OPG, were differentially expressed >3-fold, compared to control. We focused on upregulated genes in order to examine the effect of knockdown of target genes by siRNA. When mRNA expression was confirmed in each gene by RT-PCR, however, only RBP4 and PLAC8 showed the same expression pattern seen in the results from the microarray. Since there is a possibility that one week culturing may affect gene expression of PC3-GFP, expression levels of GFP, RBP4 and PLAC8 in bone tumors were examined by immunohistochemical staining. GFP-positive cells were observed in the tumors from both PC3-GFP/PC3-mock and PC3-GFP/PC3-OPG. On the other hand, the expression of RBP4 and PLAC8 was increased in tumor cells from mice injected with PC3-GFP/PC3-OPG in accordance with the results from RT-PCR and cDNA microarray analysis. These findings suggest that osteolytic tumor growth inhibition by OPG is associated with upregulation of RBP4 and PLAC8 in prostate cancer cells.

RBP4 belongs to the lipocalin family that transport small hydrophobic molecules (35) and transport retinol from the liver to peripheral tissues (36). The liver has the highest expression level of RBP4 (37), which has been shown to be a promising adipokine linking adiposity and insulin resistance in animal models and humans (38-41). Indeed, proteome analysis shows that serum RBP4 is a potential new biomarker of lung and pancreatic cancer (42,43). A direct relationship between RBP4 and cancer, however, has not been elucidated.

PLAC8, also known as onzin, is a small, highly conserved, cysteine-rich protein that is a negatively-regulated target of the c-Myc-gene. It affects cell growth and apoptosis and is highly expressed in myeloid cells and pancreatic cancer cells. Induced expression of onzin in fibroblasts promotes growth, loss of cell cycle control, resistance to apoptosis and tumorigenesis. In contrast, inhibition of endogenous expression of onzin, reduces cell growth and increases sensitivity to apoptotic stimuli (44-46).
Knockdown of RBP4 and PLAC8 in PC-3 cells by siRNA in the present study, resulted in significant inhibition of growth of PC-3 cells in vitro. This result of PLAC8 knockdown is consistent with previous reports (46). In contrast, molecular mechanisms for regulation of cancer cell growth by RBP4 must be clarified in future studies. Since the expression of RBP4 and PLAC8 were increased in tumor cells in PC3-GFP/PC3-OPG-injected mice compared to controls, RBP4 and PLAC8 may be acting as survival factors in prostate cancer cells when osteolytic tumor growth is inhibited by OPG.

In conclusion, OPG reduced osteolysis and cancer cell growth in a mouse model of bone metastasis. In addition, the expression of RBP4 and PLAC8, which were suggested to be associated with prostate cancer cell growth in vitro, was increased in remaining prostate cancer cells in bone. RBP4 and PLAC8 may become new therapeutic targets for prostate cancer bone metastasis, to be used in combination with therapies that inhibit the OPG/RANKL/RANK pathway.

Acknowledgements

We thank Megumi Kume and Hitomi Umemoto for technical assistance.

References

1. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
2. Bubendorf L, Schopfer A, Wagner U, et al: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31: 578-583, 2000.
3. Brown JE, Cook RJ, Major P, et al: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer and other solid tumors. J Natl Cancer Inst 97: 59-69, 2005.
4. Rodman GD: Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664, 2004.
5. Demers LM: Bone markers in the management of patients with skeletal metastases. Cancer 97: 874-879, 2003.
6. Percival RC, Urwin GH, Harris S, et al: Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 13: 41-49, 1987.
7. Freedland SJ, Richhariya A, Wang H, Chung K and Shore ND: Treatment patterns in patients with prostate cancer and bone metastasis among US community-based urology group practices. Urology 90: 293-298, 2012.
8. Coleman R, Grant M, Morgan G and Clezardin P: Denosumab and metastasis-free survival in men with advanced prostate cancer. Eur J Cancer 48: 3082-3092, 2012.
9. Smith MR, Egerdie B, Hernandez Toriz N, et al: Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361: 745-755, 2009.
10. Fizzi K, Lipton A, Mariette X, et al: Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27: 1564-1571, 2009.
11. Lipton A, Steger GG, Figueroa J, et al: Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25: 4431-4437, 2007.
12. Lipton A, Fizzi K, Stopeck AT, et al: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48: 3082-3092, 2012.
13. Ford JA, Jones R, Elders A, et al: Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. Eur J Cancer 49: 416-430, 2013.
14. Meeks DW, Stopeck AT, Lipton A, Body JJ, et al: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 28: 5132-5139, 2010.
15. Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45, 2001.
16. Ting HJ, Hsu J, Bao BY and Lee YF: Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by Ialpha,25-dihydroxyvitamin D3. Cancer Lett 247: 122-129, 2007.
17. Bao BY, Hu YC, Ting HJ and Lee YF: Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene 23: 3330-3360, 2004.
18. Arah IN, Song K, Seth P, Cowan KH and Sinha BK: Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells. Anticancer Res 18: 1845-1849, 1998.
19. Fisher JL, Thomas-Mudge RJ, Elliott J, et al: Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res 66: 3620-3629, 2006.
20. Flower DR: The lipocalin protein family: structure and function. Biochem J 318: 1-14, 1996.
21. Newcomer ME and Ong DE: Plasma retinol binding protein: structure and function of the prototypic lipocalin. Biochim Biophys Acta 1482: 57-64, 2000.
22. Tatsuno C, Okuno M, Tannous L, et al: Retinoids and retinoid-binding protein expression in rat adipocytes. J Biol Chem 267: 1805-1810, 1992.
23. Kovacs P, Geyer M, Berndt J, et al: Effects of genetic variation in the human retinol binding protein-4 gene (RBP4) on insulin resistance and fat depot-specific mRNA expression. Diabetes 56: 3095-3100, 2007.
24. Shipman CM and Croucher PI: Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human multiple myeloma cells. Cancer Res 63: 912-916, 2003.
25. Holen I, Croucher PI, Hamdy FC and Eaton CL: Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62: 1619-1623, 2002.
26. McGonigle JS, Giachelli CM and Scatena M: Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 12: 35-46, 2009.
27. Peddi P, Lopez-Olivo MA, Pratt GF and Suarez-Almazor ME: Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev 39: 97-104, 2013.
28. Bucay N, Sarosi I, Dunstan CR, et al: Denosumab and RANKL differentially regulate angiogenesis and endothelial cell function. Angiogenesis 12: 35-46, 2009.
39. Graham TE, Yang Q, Bluher M, et al: Retinol-binding protein 4 and insulin resistance in lean, obese and diabetic subjects. N Engl J Med 354: 2552-2563, 2006.
40. Yang Q, Graham TE, Mody N, et al: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436: 356-362, 2005.
41. Abel ED, Peroni O, Kim JK, et al: Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409: 729-733, 2001.
42. Abulaizi M, Tomonaga T, Satoh M, et al: The application of a three-step proteome analysis for identification of new biomarkers of pancreatic cancer. Int J Proteomics 2011: 628787, 2011.
43. Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR and Herndon JE II: Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 25: 5578-5583, 2007.
44. Mourtada-Maarabouni M, Watson D, Munir M, Farzaneh F and Williams GT: Apoptosis suppression by candidate oncogene PLAC8 is reversed in other cell types. Curr Cancer Drug Targets 13: 80-91, 2012.
45. Li Y, Rogulski K, Zhou Q, Sims PJ and Prochownik EV: The negative c-Myc target onzin affects proliferation and apoptosis via its obligate interaction with phospholipid scramblase 1. Mol Cell Biol 26: 3401-3413, 2006.
46. Rogulski K, Li Y, Rothermund K, et al: Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt-Mdm2-p53 pathway. Oncogene 24: 7524-7541, 2005.